Additional discussions with the content in the pharmaceutical Neighborhood of every submodel are necessary to obtain a common template, similar to the attempts in I4.0 with the IDTA 21 Figure 2.1 shows how an AAS is used and transferred amongst a provider and an integrator. The supplier makes the AAS for their assets (products D1 with two diffe